HuGE Literature Finder
Records
1
-
30
| Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non?small?cell lung cancer: A meta analysis. Clinics (Sao Paulo, Brazil) 2023 1 78 100152. Yi Min, He Ting, Wang Kaijin, Wei Yongga |
| Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis. Thoracic cancer 2023 1 14 (6): 535-543. Dai Jiali, Liu Xinyin, Li Jun, Qu Tianyu, Cui Yanan, Jin Shidai, Zhang Erbao, Guo Renh |
| Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials. World journal of surgical oncology 2023 2 21 (1): 45. Zhao Ning, Wu Zhuo-Peng, Yang Jie, Feng Wei-Neng, Yang Sheng-Li, Luo Ying, Ye Jun, Wang Fei, Zhang Xiao-Wen, Xiao Ye, Wu Ling-Ling, Gu Wei-Qu |
| Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. Oncology letters 2023 1 25 (2): 62. Obradovic Jasmina, Todosijevic Jovana, Jurisic Vladim |
| Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis. Oncology letters 2022 Nov 24 (5): 384. Lan Bo, Zhao Na, Du Kang, Leng Baola |
| Computed tomography-guided lung biopsy for molecular tests: a meta-analysis. Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery 2022 Jun 19 (2): 96-101. Zhang Jian-Hua, Xia Feng-Fei, Yang Xiao-Shan, Li |
| Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. Journal of clinical medicine 2022 Jun 11 (12): . Lee Tai-Huang, Chen Hsiao-Ling, Chang Hsiu-Mei, Wu Chiou-Mei, Wu Kuan-Li, Kuo Chia-Yu, Wei Po-Ju, Chen Chin-Ling, Liu Hui-Lin, Hung Jen-Yu, Yang Chih-Jen, Chong Inn-W |
| Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open 2022 Jun 7 (3): 100507. Dafni U, Soo R A, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J-Y, De Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R |
| Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Targeted oncology 2022 Feb . Van Sanden Suzy, Murton Molly, Bobrowska Anna, Rahhali Nora, Sermon Jan, Rodrigues Bernardo, Goff-Leggett Danielle, Chouaid Christos, Sebastian Martin, Greystoke Alasta |
| Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2022 Jan 166 9-16. Huang Le-Tian, Zhang Shu-Ling, Han Cheng-Bo, Ma Jie-T |
| A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer. Medicine 2022 12 101 (47): e31894. Cui Ran, Wei Chun, Li Xianyi, Jiang |
| Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. Future oncology (London, England) 2022 6 18 (21): 2695-2707. Tian Wentao, Tan Nuopei, Ke Jiawen, Zou Ji'an, Liu Xiaohan, Pan Yue, Zeng Yue, Peng Yurong, Wu Fa |
| Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis. Thrombosis research 2022 3 213 47-56. Abufarhaneh Mohammed, Pandya Rudra Kashyap, Alkhaja Ahmed, Iansavichene Alla, Welch Stephen, Lazo-Langner Alejand |
| Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis. European journal of radiology open 2022 2 9 100400. Ortiz Andrés Felipe Herrera, Camacho Tatiana Cadavid, Vásquez Andrés Francisco, Del Castillo Herazo Valeria, Neira Juan Guillermo Arámbula, Yepes María Mónica, Camacho Eduard Cadav |
| Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis. International journal of clinical practice 2022 6 2022 3102641. Xia Jun, Zhu Jiping, Li Lei, Xu Shiq |
| Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC cancer 2022 3 22 (1): 328. Zhao Pengfei, Zhen Hongchao, Zhao Hong, Zhao Lei, Cao Bangw |
| Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. Future oncology (London, England) 2022 8 18 (27): 3055-3065. Li Xue, Wang Fang, Jia Huijun, Lian Zhen, Ren Kai, Yuan Zhiyong, Wang Ping, Zhao Luj |
| Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353. Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J |
| Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis. Future oncology (London, England) 2022 2 18 (9): 1159-1169. Li Meichen, Hou Xue, Lin Suxia, Zheng Lie, Liang Jianzhong, Chen Jing, Wang Na, Zhang Baishen, Chen Lik |
| Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis. Frontiers in oncology 2022 12 863666. Yi Xiao-Fang, Song Jun, Gao Ruo-Lin, Sun Li, Wu Zhi-Xuan, Zhang Shu-Ling, Huang Le-Tian, Ma Jie-Tao, Han Cheng- |
| EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review. Medicina (Kaunas, Lithuania) 2022 11 58 (11): . Chen Chang-Hung, Chou Deng-Wei, Chung Kuo-Mou, Chang Han- |
| Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ open 2022 8 12 (8): e062036. Deng Wusheng, Wang Ke, Jiang Yun, Li Dingbin, Bao Chongxi, Luo Jing, Liu Liuyuan, Huang Bing, Kong Jinlia |
| First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. Therapeutic advances in chronic disease 2022 10 13 20406223221125706. Chen Chongxiang, Zhang Chunning, Lin Huaming, Liu Qianyin, Wu Limian, Zhou Chengzhi, Zhang Jiex |
| Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. Technology in cancer research & treatment 2022 9 21 15330338221128414. Sun Dantong, Tao Junyan, Yan Weihua, Zhu Jingjuan, Zhou Hai, Sheng Yingying, Xue Chaofan, Li Hong, Hou Hel |
| Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis. Immunotherapy 2022 7 14 (12): 945-956. Wang Yan, He Haiy |
| RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis. Frontiers in oncology 2022 12 12 1024833. Wu Min, Jiang Jun, Zhang Xuewen, Chen Jie, Chang Qiaomei, Chen Ro |
| Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular diagnosis & therapy 2021 Nov . Melosky Barbara, Kambartel Kato, Häntschel Maik, Bennetts Margherita, Nickens Dana J, Brinkmann Julia, Kayser Antonin, Moran Michael, Cappuzzo Federi |
| Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. Journal of oncology 2021 12 2021 8736288. Zhang Lemeng, Luo Yongzhong, Chen Jianhua, Cheng Tianli, Yang Hua, Pan Changqie, Li Haitao, Jiang Zh |
| Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. Frontiers in oncology 2021 11 752918. Araujo Jhajaira M, Rosas Gina, Belmar-López Carolina, Raez Luis E, Rolfo Christian D, Schwarz Luis J, Infante-Huaytalla Ulises, Paez Kevin J, García Luis R, Alvarado Hober, Ramos Fany P, Delgado-Espinoza Sheyla S, Cardenas-Farfan Jhon B, Cornejo Melanie, Zanabria Daniel, Colonio-Cossio Christian, Rojas-Jefferson Mario, Pinto Joseph |
| REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis. Pakistan journal of pharmaceutical sciences 2021 11 34 (4): 1459-1468. Hou Bing, Lu Xiao, Gao Dong-Cai, Liu Quan-Xing, Zhou Dong, Zheng Hong, Dai Ji-Ga |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 31, 2023
- Content source: